News & Updates

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

04 Aug 2021 by

Adjuvant olaparib for 1 year following local treatment and adjuvant/neoadjuvant chemotherapy improved disease-free survival (DFS) in patients with HER2-negative early breast cancer (EBC) with BRCA1 or BRCA2 pathogenic/likely pathogenic variants and high recurrence risk, according to interim results of the multinational, phase III OlympiA study.

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

04 Aug 2021

Treatment-related amenorrhea common in young breast cancer patients

04 Aug 2021

Young women with breast cancer who are receiving treatment with modern chemotherapy regimens are likely to develop short episodes of treatment-related amenorrhea, but the vast majority of them will maintain or regain menstrual function, a study has found.

Treatment-related amenorrhea common in young breast cancer patients

04 Aug 2021

Multitarget FIT better than standard test for colorectal cancer screening

02 Aug 2021

A multitarget faecal immunochemical test (mtFIT) is more accurate than conventional FIT in detecting advanced neoplasia due to an increased detection of advanced adenomas, according to a study.

Multitarget FIT better than standard test for colorectal cancer screening

02 Aug 2021

Taiwan study: No link between drinking and pancreatic cancer

27 Jul 2021

Alcohol consumption does not seem to substantially impact population occurrence rates of pancreatic cancer, a recent Taiwan study has found. This null effect seems to hold even among people who are genetically susceptible to the carcinogenicity of alcohol.

Taiwan study: No link between drinking and pancreatic cancer

27 Jul 2021

Targeted radioligand therapy ups survival in previously-treated mCRPC

27 Jul 2021 by

Adding the lutetium-labelled PSMA*-617 (177Lu PSMA-617) targeted radioligand therapy to standard of care (SOC) led to significant extension of radiographic progression-free survival (rPFS) and overall survival (OS) compared with SOC alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after treatment with chemotherapy and androgen inhibitors, according to the VISION trial presented at ASCO 2021.

Targeted radioligand therapy ups survival in previously-treated mCRPC

27 Jul 2021

No excess risk of gastrointestinal malignancies with ranitidine vs other reflux drugs

27 Jul 2021

Use of the histamine-2 receptor antagonist ranitidine does not appear to increase the likelihood of developing gastrointestinal malignancies as compared with omeprazole or famotidine, as shown in a study.

No excess risk of gastrointestinal malignancies with ranitidine vs other reflux drugs

27 Jul 2021

Folate intake lowers colorectal cancer risk in women

26 Jul 2021

Folate intake, whether in total or synthetic form, leads to a reduction in overall colorectal cancer (CRC) incidence following long latency periods, according to a US study. No evidence shows that high folate intake in the postfortification period is associated with a higher CRC risk in the female population.

Folate intake lowers colorectal cancer risk in women

26 Jul 2021

Early menopause carries heightened risk of lung cancer in smokers

24 Jul 2021

Women who experience early menopause appear to be at increased risk of developing lung cancer, but this association is limited to smokers, according to the results of a meta-analysis.

Early menopause carries heightened risk of lung cancer in smokers

24 Jul 2021

Mail-out faecal immunochemical test kits help increase CRC screening

23 Jul 2021

The implementation of an organized mailed faecal immunochemical test (FIT) outreach programme in a safety-net health system appears to increase FIT completion and improve colorectal cancer screening, according to a study.

Mail-out faecal immunochemical test kits help increase CRC screening

23 Jul 2021

$Ultra hypofractionated RT safe, effective for older patients with invasive bladder cancer$

Ultra hypofractionated RT safe, effective for older patients with invasive bladder cancer

21 Jul 2021

For older patients with invasive bladder cancer who are unfit for radical treatment, they may opt for weekly ultra hypofractionated intensity modulated radiotherapy (RT) with image guidance and bladder training, which is found to be an effective, safe, and well-tolerated regimen, suggests a study.

Ultra hypofractionated RT safe, effective for older patients with invasive bladder cancer

21 Jul 2021

News & Updates

Filter by Specialty:

Specialty:

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

Treatment-related amenorrhea common in young breast cancer patients

Treatment-related amenorrhea common in young breast cancer patients

Multitarget FIT better than standard test for colorectal cancer screening

Multitarget FIT better than standard test for colorectal cancer screening

Taiwan study: No link between drinking and pancreatic cancer

Taiwan study: No link between drinking and pancreatic cancer

Targeted radioligand therapy ups survival in previously-treated mCRPC

Targeted radioligand therapy ups survival in previously-treated mCRPC

No excess risk of gastrointestinal malignancies with ranitidine vs other reflux drugs

No excess risk of gastrointestinal malignancies with ranitidine vs other reflux drugs

Folate intake lowers colorectal cancer risk in women

Folate intake lowers colorectal cancer risk in women

Early menopause carries heightened risk of lung cancer in smokers

Early menopause carries heightened risk of lung cancer in smokers

Mail-out faecal immunochemical test kits help increase CRC screening

Mail-out faecal immunochemical test kits help increase CRC screening

Ultra hypofractionated RT safe, effective for older patients with invasive bladder cancer

Ultra hypofractionated RT safe, effective for older patients with invasive bladder cancer